+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma

Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma

Journal of Clinical Oncology 26(4): 535-541

No primary lesion is identified in 10% to 20% of patients presenting with palpable evidence of regional metastatic melanoma. Because the prognostic significance of unknown primary melanoma (MUP) is unclear, we compared clinical outcomes of patients with MUP and known primary melanoma (MKP) with regional nodal metastases. We reviewed our 13,000-patient prospective melanoma database (1971 through 2005) to identify patients managed with regional lymphadenectomy for palpable nodal metastases from MUP or MKP. Multivariate analysis identified prognostic factors significant for survival. MUP and MKP were then matched by significant covariates. Overall survival (OS) was estimated by Kaplan-Meier method and compared by log-rank analysis. Multivariate analysis of data from 1,571 study patients identified four significant covariates associated with worse prognosis: age >or= 60 years (hazard ratio [HR] = 1.294; P = .0017), male sex (HR = 1.335; P = .0004), nodal tumor burden >or= one (HR = 1.256; P < .0001), and known primary (HR = 1.507; 95% CI, 1.220 to 1.862; P = .0001). Five-year OS was significantly higher for 262 patients with MUP than for 1,309 patients with MKP (55% +/- 6% v 44% +/- 3%; P = .0021). Computerized matching of MUP and MKP by four significant covariates (age, sex, nodal tumor burden, and decade of diagnosis) yielded 221 matched pairs. Median and 5-year OS rates were 165 months and 58% +/- 7%, respectively, for MUP as compared with 34 months and 40% +/- 7%, respectively, for MKP (P = .0006). Lymphadenectomy is effective for nodal metastasis from MUP. The significantly better postoperative survival for MUP versus MKP suggests a strong endogenous immune response against the primary melanoma. Immunologic studies to identify cell-mediated and antibody components of this response may lead to new approaches for determining melanoma prognosis and treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 053746907

Download citation: RISBibTeXText

PMID: 18235114

DOI: 10.1200/JCO.2007.14.0285

Related references

Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour. Plos One 8(6): E66953-E66953, 2014

Management decisions for nodal metastasis from an unknown primary melanoma. American Journal of Hematology/Oncology 7(7): 306-308, 2008

Improved survival for stage IV melanoma from an unknown primary site. Journal of Clinical Oncology 27(21): 3489-3495, 2009

Improved survival for stage IV melanoma from an unknown primary site. Journal of Clinical Oncology 26(15_suppl): 9031-9031, 2016

A meticulous lymphadenectomy may improve survival in invasive bladder cancer The influence of location nodal metastasis. Journal of Urology 155(5 SUPPL ): 627A, 1996

Lymph nodal Merkel cell carcinoma: primary tumor or metastasis from unknown primary site?. Journal of Cutaneous Pathology 38(10): 836-837, 2012

Primary Solitary Melanoma of the Lymphatic Nodes Or a Single Metastasis of Unknown Melanoma: Do We Need a New Staging System?. Open Access Macedonian Journal of Medical Sciences 5(7): 970-973, 2018

Retroperitoneal nodal metastasis in primary adult type granulosa cell tumor of the ovary: Can routine lymphadenectomy be omitted?. European Journal of Obstetrics, Gynecology, and Reproductive Biology 219: 70-73, 2017

Melanoma of unknown primary with nodal metastases, presenting with vitiligo-like depigmentation. Giornale Italiano di Dermatologia E Venereologia 147(2): 210-211, 2012

Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease. Annals of Surgical Oncology 21(9): 3108-3116, 2015

Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site. Annals of Surgical Oncology 21(13): 4317-4323, 2015

Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. American Surgeon 77(8): 1009-1013, 2011

Improved Long-term Survival After Lymphadenectomy of Melanoma Metastatic to Regional Nodes. Annals of Surgery 214(4): 491-501, 1991

Metastasis from melanoma of unknown primary location. Tumori 55(6): 403-408, 1969

Renal metastasis of malignant melanoma with unknown primary. Urology 69(2): 384.E9-10, 2007